Using NF-kB ‘fingerprints to identify therapeutic vulnerabilities within subsets of B cell malignancies

This exciting Blood Cancer UK funded project grant utilises the novel NF-kB fingerprinting technology developed by a collaboration between the Pepper and Mitchell team (www.mitchell.science) to predict the best drugs for patients with B cell malignancies.